Sung Uk Lee1, Sung Ho Moon2,3,4, Kwan Ho Cho1, Hong Ryull Pyo5, Joo Young Kim1, Dae Yong Kim1, Tae Hyun Kim1, Yang-Gun Suh1, Yeon-Joo Kim1. 1. Proton Therapy Center, Research Institute and Hospital, National Cancer Center, Goyang, Republic of Korea. 2. Proton Therapy Center, Research Institute and Hospital, National Cancer Center, Goyang, Republic of Korea. shmoon@ncc.re.kr. 3. Center for Lung Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Republic of Korea. shmoon@ncc.re.kr. 4. Proton Therapy Center, Research Institute and Hospital, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do, 410-769, Republic of Korea. shmoon@ncc.re.kr. 5. Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Abstract
PURPOSE: To evaluate the efficacy and safety of ablative dose hypofractionated proton beam therapy (PBT) for patients with stage I and recurrent non-small cell lung carcinoma (NSCLC). PATIENTS AND METHODS: A total of 55 patients with stage I (n = 42) and recurrent (n = 13) NSCLC underwent hypofractionated PBT and were retrospectively reviewed. A total dose of 50-72 CGE (cobalt gray equivalent) in 5-12 fractions was delivered. RESULTS: The median follow-up duration was 29 months (range 4-95 months). There were 24 deaths (43.6%) during the follow-up period: 11 died of disease progression and 13 from other causes. Kaplan-Meier overall survival rate (OS) at 3 years was 54.9% and the median OS was 48.6 months (range 4-95 months). Local progression was observed in 7 patients and the median time to local progression was 9.3 months (range 5-14 months). Cumulative actuarial local control rate (LCR), lymph node metastasis-free survival, and distant metastasis-free survival rates at 3 years were 85.4, 78.4, and 76.5%, respectively. Larger tumor diameter was significantly associated with poorer LCR (3-year: 94% for ≤3 cm vs. 65% for >3 cm, p = 0.006) on univariate analysis and also an independent prognostic factor for LCR (HR 6.9, 95% CI = 1.3-37.8, p = 0.026) on multivariate analysis. No grade 3 or 4 treatment-related toxicities developed. One grade 5 treatment-related adverse event occurred in a patient with symptomatic idiopathic pulmonary fibrosis. CONCLUSIONS: Ablative dose hypofractionated PBT was safe and promising for stage I and recurrent NSCLC.
PURPOSE: To evaluate the efficacy and safety of ablative dose hypofractionated proton beam therapy (PBT) for patients with stage I and recurrent non-small cell lung carcinoma (NSCLC). PATIENTS AND METHODS: A total of 55 patients with stage I (n = 42) and recurrent (n = 13) NSCLC underwent hypofractionated PBT and were retrospectively reviewed. A total dose of 50-72 CGE (cobalt gray equivalent) in 5-12 fractions was delivered. RESULTS: The median follow-up duration was 29 months (range 4-95 months). There were 24 deaths (43.6%) during the follow-up period: 11 died of disease progression and 13 from other causes. Kaplan-Meier overall survival rate (OS) at 3 years was 54.9% and the median OS was 48.6 months (range 4-95 months). Local progression was observed in 7 patients and the median time to local progression was 9.3 months (range 5-14 months). Cumulative actuarial local control rate (LCR), lymph node metastasis-free survival, and distant metastasis-free survival rates at 3 years were 85.4, 78.4, and 76.5%, respectively. Larger tumor diameter was significantly associated with poorer LCR (3-year: 94% for ≤3 cm vs. 65% for >3 cm, p = 0.006) on univariate analysis and also an independent prognostic factor for LCR (HR 6.9, 95% CI = 1.3-37.8, p = 0.026) on multivariate analysis. No grade 3 or 4 treatment-related toxicities developed. One grade 5 treatment-related adverse event occurred in a patient with symptomatic idiopathic pulmonary fibrosis. CONCLUSIONS: Ablative dose hypofractionated PBT was safe and promising for stage I and recurrent NSCLC.
Authors: René W M Underberg; Frank J Lagerwaard; Ben J Slotman; Johan P Cuijpers; Suresh Senan Journal: Int J Radiat Oncol Biol Phys Date: 2005-09-01 Impact factor: 7.038
Authors: Robert Timmerman; James Galvin; Jeff Michalski; William Straube; Geoffrey Ibbott; Elizabeth Martin; Ramzi Abdulrahman; Suzanne Swann; Jack Fowler; Hak Choy Journal: Acta Oncol Date: 2006 Impact factor: 4.089
Authors: K Ohara; T Okumura; M Akisada; T Inada; T Mori; H Yokota; M J Calaguas Journal: Int J Radiat Oncol Biol Phys Date: 1989-10 Impact factor: 7.038
Authors: Shivam M Kharod; R Charles Nichols; Randal H Henderson; Christopher G Morris; Dat C Pham; Vandana K Seeram; Lisa M Jones; Maria Antonio-Miranda; Daniel A Siragusa; Zuofeng Li; Stella Flampouri; Bradford S Hoppe Journal: Int J Part Ther Date: 2020-11-06